Chromatin Remodeling and Pregnancy-Induced Differentiation

  • Jose Russo
  • Irma H. Russo


Breast cancer is the most frequently diagnosed cancer in postmenopausal women and the leading cause of cancer death in females worldwide [1]. The global incidence of breast cancer has gradually increased over the last few decades [1, 2]. Although the reasons of this increase are uncertain, it is known that the breast cancer risk is reduced in women who gave birth to a child before age 24 [3] a reduction that is enhanced by breast-feeding and multiparity [4, 5]. Experimentally it has been demonstrated that the protection conferred by pregnancy is mediated by the differentiation of the breast, a physiological process driven by the complex hormonal milieu created by the placenta and the fetus [6–8]. The postulate that the degree of differentiation acquired through an early pregnancy changes the genomic signature that differentiates the lobular structures of early parous (P) women from those of nulliparous (NP) women has been demonstrated through the enriched analysis of the genomic profile of breasts of parous and nulliparous postmenopausal and premenopausal women [9, 10] and of rodent models [6–8, 11, 12]. These findings have allowed researchers to demonstrate that significant differences in the expression of genes controlling differentiation and transcription exist between groups that differ in their parity history. These data explain at molecular level the basis of the protective effect of pregnancy and establishes a functional genomic signature of breast cancer risk reduction, confirming a postulate published in 1997 [7].


Mammary Gland Breast Cancer Risk Chromatin Remodel Nulliparous Woman Parous Woman 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We, the authors, acknowledge the contributions of the many members of the Breast Cancer Research Laboratory at the Fox Chase Cancer Center, especially Drs. Y Su, R. Lopez, and F. Sheriff, who have worked with us to generate the data described in Sect. 7.8 incorporated into this chapter and allowed us to elaborate it into a unified concept.


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  2. 2.
    Harford JB (2011) Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol 12:306–312PubMedCrossRefGoogle Scholar
  3. 3.
    MacMahon B, Cole P, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Valaoras VG, Yuasa S (1970) Age at first birth and breast cancer risk. Bull World Health Organ 43:209–221PubMedGoogle Scholar
  4. 4.
    Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2001) Grand multiparity and the risk of breast cancer: population-based study in Finland. Cancer Causes Control 12:491–500PubMedCrossRefGoogle Scholar
  5. 5.
    Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103:250–263PubMedCrossRefGoogle Scholar
  6. 6.
    Russo IH, Koszalka M, Russo J (1991) Comparative study of the influence of pregnancy and hormonal treatment on mammary carcinogenesis. Br J Cancer 64:481–484PubMedCrossRefGoogle Scholar
  7. 7.
    Russo J, Russo IH (1997) Role of differentiation in the pathogenesis and prevention of breast cancer. Endocr Relat Cancer 4:7–21CrossRefGoogle Scholar
  8. 8.
    Russo J, Russo IH (eds) (2004) Molecular basis of breast cancer: prevention and treatment. Springer, Berlin, p 447Google Scholar
  9. 9.
    Russo J, Balogh GA, Russo IH (2008) Full-term pregnancy induces a specific genomic signature in the human breast. Cancer Epidemiol Biomarkers Prev 17:51–66PubMedCrossRefGoogle Scholar
  10. 10.
    Asztalos S, Gann PH, Hayes MK, Nonn L, Beam CA, Dai Y, Wiley EL, Tonetti DA (2010) Gene expression patterns in the human breast after pregnancy. Cancer Prev Res 3:301–311CrossRefGoogle Scholar
  11. 11.
    Medina D (2004) Breast cancer: the protective effect of pregnancy. Clin Cancer Res 10:380S–384SPubMedCrossRefGoogle Scholar
  12. 12.
    D’Cruz CM, Moody SE, Master SR, Hartman JL, Keiper EA, Imielinski MB, Cox JD, Wang JY, Ha SI, Keister BA, Chodosh LA (2002) Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. Mol Endocrinol 16:2034–2051PubMedCrossRefGoogle Scholar
  13. 13.
    Belitskaya-Levy I, Zeleniuch-Jacquotte A, Russo J, Russo IH, Bordas P, Ahman J, Afanasyeva Y, Johansson R, Lenner P, Li X, de Cicco-Lopez RL, Peri S, Ross E, Russo PA, Santucci-Pereira J, Sheriff FS, Slifker M, Hallmans G, Toniolo P, Arslan AA (2011) Characterization of a genomic signature of pregnancy identified in the breast. Cancer Prev Res 4:1457–1464CrossRefGoogle Scholar
  14. 14.
    Russo J, Rivera R, Russo IH (1992) Influence of age and parity on the development of the human breast. Breast Cancer Res Treat 23:211–218PubMedCrossRefGoogle Scholar
  15. 15.
    Russo IH, Russo J (2011) Pregnancy-induced changes in breast cancer risk. J Mammary Gland Biol Neoplasia 16:221–233PubMedCrossRefGoogle Scholar
  16. 16.
    Long JC, Caceres JF (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417:15–27PubMedCrossRefGoogle Scholar
  17. 17.
    Herrmann A, Fleischer K, Czajkowska H, Muller-Newen G, Becker W (2007) Characterization of cyclin L1 as an immobile component of the splicing factor compartment. FASEB J 21:3142–3152PubMedCrossRefGoogle Scholar
  18. 18.
    Golob JL, Paige SL, Muskheli V, Pabon L, Murry CE (2008) Chromatin remodeling during mouse and human embryonic stem cell differentiation. Dev Dyn 237:1389–1398PubMedCrossRefGoogle Scholar
  19. 19.
    Wilson BJ, Giguere V (2008) Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway. Mol Cancer 7:49PubMedCrossRefGoogle Scholar
  20. 20.
    Chou J, Provot S, Werb Z (2010) GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol 222:42–49PubMedCrossRefGoogle Scholar
  21. 21.
    Russo IH, Russo J (1996) Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938–967PubMedCrossRefGoogle Scholar
  22. 22.
    Russo J, Tait L, Russo IH (1983) Susceptibility of the mammary gland to carcinogenesis. III. The cell of origin of rat mammary carcinoma. Am J Pathol 113:50–66PubMedGoogle Scholar
  23. 23.
    Bussolati G, Marchio C, Gaetano L, Lupo R, Sapino A (2008) Pleomorphism of the nuclear envelope in breast cancer: a new approach to an old problem. J Cell Mol Med 12:209–218PubMedCrossRefGoogle Scholar
  24. 24.
    Tan PH, Goh BB, Chiang G, Bay BH (2001) Correlation of nuclear morphometry with pathologic parameters in ductal carcinoma in situ of the breast. Mod Pathol 14:937–941PubMedCrossRefGoogle Scholar
  25. 25.
    Palmer JE, Sant Cassia LJ, Irwin CJ, Morris AG, Rollason TP (2008) The prognostic value of nuclear morphometric analysis in serous ovarian carcinoma. Int J Gynecol Cancer 18:692–701PubMedCrossRefGoogle Scholar
  26. 26.
    Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298:1039–1043PubMedCrossRefGoogle Scholar
  27. 27.
    Kubicek S, Schotta G, Lachner M, Sengupta R, Kohlmaier A, Perez-Burgos L, Linderson Y, Martens JH, O’Sullivan RJ, Fodor BD, Yonezawa M, Peters AH, Jenuwein T (2006) The role of histone modifications in epigenetic transitions during normal and perturbed development. Ernst Schering Res Found Workshop 57:1–27PubMedCrossRefGoogle Scholar
  28. 28.
    Lin W, Dent SY (2006) Functions of histone-modifying enzymes in development. Curr Opin Genet Dev 16:137–142PubMedCrossRefGoogle Scholar
  29. 29.
    Guenther MG, Young RA (2010) Transcription. Repressive transcription. Science 329:150–151PubMedCrossRefGoogle Scholar
  30. 30.
    Erwin JA, Lee JT (2010) Characterization of X-chromosome inactivation status in human pluripotent stem cells. Curr Protoc Stem Cell Biol Chapter 1:Unit 1B.6Google Scholar
  31. 31.
    Navarro P, Chambers I, Karwacki-Neisius V, Chureau C, Morey C, Rougeulle C, Avner P (2008) Molecular coupling of Xist regulation and pluripotency. Science 321:1693–1695PubMedCrossRefGoogle Scholar
  32. 32.
    Surani MA, Hayashi K, Hajkova P (2007) Genetic and epigenetic regulators of pluripotency. Cell 128:747–762PubMedCrossRefGoogle Scholar
  33. 33.
    Lee J (2010) Characterization of X-chromosome inactivation status in human pluripotent stem cells. Curr Protoc Stem Cell Biol Chapter 1:Unit 1B.6Google Scholar
  34. 34.
    Taga Y, Miyoshi M, Okajima T, Matsuda T, Nadano D (2010) Identification of heterogeneous nuclear ribonucleoprotein A/B as a cytoplasmic mRNA-binding protein in early involution of the mouse mammary gland. Cell Biochem Funct 28:321–328PubMedCrossRefGoogle Scholar
  35. 35.
    Huang PR, Hung SC, Wang TC (2010) Telomeric DNA-binding activities of heterogeneous nuclear ribonucleoprotein A3 in vitro and in vivo. Biochim Biophys Acta 1803:1164–1174PubMedCrossRefGoogle Scholar
  36. 36.
    Han SP, Friend LR, Carson JH, Korza G, Barbarese E, Maggipinto M, Hatfield JT, Rothnagel JA, Smith R (2010) Differential subcellular distributions and trafficking functions of hnRNP A2/B1 spliceoforms. Traffic 11:886–898PubMedCrossRefGoogle Scholar
  37. 37.
    Loyer P, Trembley JH, Grenet JA, Busson A, Corlu A, Zhao W, Kocak M, Kidd VJ, Lahti JM (2008) Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: influence of cyclin L isoforms on splice site selection. J Biol Chem 283:7721–7732PubMedCrossRefGoogle Scholar
  38. 38.
    Yang L, Li N, Wang C, Yu Y, Yuan L, Zhang M, Cao X (2004) Cyclin L2, a novel RNA polymerase II-associated cyclin, is involved in pre-mRNA splicing and induces apoptosis of human hepatocellular carcinoma cells. J Biol Chem 279:11639–11648PubMedCrossRefGoogle Scholar
  39. 39.
    Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY (2008) Up-regulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci U S A 105:15708–15713PubMedCrossRefGoogle Scholar
  40. 40.
    Kobayashi T, Ishida J, Musashi M, Ota S, Yoshida T, Shimizu Y, Chuma M, Kawakami H, Asaka M, Tanaka J, Imamura M, Kobayashi M, Itoh H, Edamatsu H, Sutherland LC, Brachmann RK (2011) p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer 128:304–318PubMedCrossRefGoogle Scholar
  41. 41.
    Salomonis N, Schlieve CR, Pereira L, Wahlquist C, Colas A, Zambon AC, Vranizan K, Spindler MJ, Pico AR, Cline MS, Clark TA, Williams A, Blume JE, Samal E, Mercola M, Merrill BJ, Conklin BR (2010) Alternative splicing regulates mouse embryonic stem cell pluripotency and differentiation. Proc Natl Acad Sci U S A 107:10514–10519PubMedCrossRefGoogle Scholar
  42. 42.
    Russo J, Russo IH (2000) Human chorionic gonadotropin in breast cancer prevention. In: Ethier SP (ed) Endocrine oncology. Humana Press, Totowa, NJ, pp 121–136CrossRefGoogle Scholar
  43. 43.
    Russo J, Mailo D, Hu YF, Balogh G, Sheriff F, Russo IH (2005) Breast differentiation and its implication in cancer prevention. Clin Cancer Res 11:931s–936sPubMedGoogle Scholar
  44. 44.
    Russo IH, Russo J (2000) Hormonal approach to breast cancer prevention. J Cell Biochem Suppl 34:1–6PubMedCrossRefGoogle Scholar
  45. 45.
    Russo J, Moral R, Balogh GA, Mailo D, Russo IH (2005) The protective role of pregnancy in breast cancer. Breast Cancer Res 7:131–142PubMedCrossRefGoogle Scholar
  46. 46.
    Russo J, Balogh GA, Chen J, Fernandez SV, Fernbaugh R, Heulings R, Mailo DA, Moral R, Russo PA, Sheriff F, Vanegas JE, Wang R, Russo IH (2006) The concept of stem cell in the mammary gland and its implication in morphogenesis, cancer and prevention. Front Biosci 11:151–172PubMedCrossRefGoogle Scholar
  47. 47.
    Russo J, Russo IH (1994) Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 3:353–364PubMedGoogle Scholar
  48. 48.
    Russo J, Russo IH (1987) Biological and molecular bases of mammary carcinogenesis. Lab Invest 57:112–137PubMedGoogle Scholar
  49. 49.
    Russo IH, Russo J (2007) Primary prevention of breast cancer by hormone-induced differentiation. Recent Results Cancer Res 174:111–130PubMedCrossRefGoogle Scholar
  50. 50.
    Kocdor H, Kocdor MA, Russo J, Snider KE, Vanegas JE, Russo IH, Fernandez SV (2009) Human chorionic gonadotropin (hCG) prevents the transformed phenotypes induced by 17 beta-estradiol in human breast epithelial cells. Cell Biol Int 33:1135–1143PubMedCrossRefGoogle Scholar
  51. 51.
    Russo J, Santucci-Pereira J, López de Cicco R, Sheriff F, Russo PA, Peri S, Slifker M, Ross E, Mello MLS, Vidal BC, Belitskaya-Lévy I, Arslan A, Zeleniuch-Jacquotte A, Bordas P, Lenner P, Ahman J, Afanasyeva Y, Hallmans G, Toniolo P, Russo IH (2012) Pregnancy-induced chromatin remodeling in the breast of postmenopausal women. Int J Cancer 131(5):1059–1070. doi: 10.1002/ijc.27323 PubMedCrossRefGoogle Scholar
  52. 52.
    Mello ML, Vidal BC, Russo IH, Lareef MH, Russo J (2007) DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182,780 as assessed by image analysis. Mutat Res 617:1–7PubMedCrossRefGoogle Scholar
  53. 53.
    Mello ML, Russo P, Russo J, Vidal BC (2009) Entropy of Feulgen-stained 17-beta-estradiol-transformed human breast epithelial cells as assessed by restriction enzymes and image analysis. Oncol Rep 21:1483–1487PubMedCrossRefGoogle Scholar
  54. 54.
    Doudkine A, Macaulay C, Poulin N, Palcic B (1995) Nuclear texture measurements in image cytometry. Pathologica 87:286–299PubMedGoogle Scholar
  55. 55.
    Isharwal S, Miller MC, Marlow C, Makarov DV, Partin AW, Veltri RW (2008) p300 (histone acetyltransferase) biomarker predicts prostate cancer biochemical recurrence and correlates with changes in epithelia nuclear size and shape. Prostate 68:1097–1104PubMedCrossRefGoogle Scholar
  56. 56.
    Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185–193PubMedCrossRefGoogle Scholar
  57. 57.
    Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8:118–127PubMedCrossRefGoogle Scholar
  58. 58.
    Smyth GK (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W (eds) Bioinformatics and computational biology solutions using R and bioconductor. Springer, New York, pp 397–420CrossRefGoogle Scholar
  59. 59.
    Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, Hornik K, Hothorn T, Huber W, Iacus S, Irizarry R, Leisch F, Li C, Maechler M, Rossini AJ, Sawitzki G, Smith C, Smyth G, Tierney L, Yang JY, Zhang J (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 5:R80PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Jose Russo
    • 1
  • Irma H. Russo
    • 1
  1. 1.Breast Cancer Research LaboratoryFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations